• HOME
• ABOUT US
  • Company Profile
  • CRO's & Pharmaceutical Companies
• COMPANY BIOS
  • Jeff Stein
  • David M. Radin, MD
  • Judith Dalgin
  • Svetlana Konnov, LPN
  • Betsy Kempner, RN
  • Patrick Brew, MD, RN
  • Tulie Brew, MD
  • Anju Sherstha, MD
• CURRENT TRIALS
  • Chronic Lower Back Pain
  • Chronic Pain
  • Interstitial Cystitis / Painful Bladder Syndrome
  • Osteoarthritis
• CONDITIONS
• CONTACT US

Interstitial Cystitis / Painful Bladder Syndrome

Stamford Therapeutics Consortium is currently conducting a Phase II study on interstitial cystitis/ painful bladder syndrome (IC/PBS) sponsored by Pfizer.

Summary: The purpose of the study is to test the efficacy and safety of several dose levels of tanezumab for reducing pain with sufficient tolerability.

www.bladderpainstudy.com

For More Information Please Contact:
Judy Dalgin (Site Manager)
email: jdalgin@stctrials.com
telephone: 203-325-8529


Eligibility:

• Ages Eligible for Study: 18 Years to 75 years

• Genders Eligible for Study: Both

• Accepts Healthy Volunteers: No


Partial Inclusion Criteria:

• Patients with interstitial cystitis/ painful bladder syndrome for more than 6 months with moderate to severe pain and a micturition frequency greater than 7 per day.

• Patients who have been on stable oral medicines for interstitial cystitis/ painful bladder syndrome for at least 3 months. Other therapies might need to be stopped.


Partial Exclusion Criteria:

• Patients on certain recent treatments for interstitial cystitis/ painful bladder syndrome.

• Body mass index (BMI) of >39 kg/m2.

• History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.

• Patients with peripheral neuropathy.

• Patients with Type I or type II diabetes mellitus who have an HbA1c > 8.0%.